Issue #28 AI, radar, LiDARâtwo small caps turning car tech into the next trillion-dollar opportunity. The automotive world is transforming faster than ever â where cars are no longer just machines, but intelligent systems powered by silicon. From autonomous driving and ADAS to AI-powered chip architectures, the line between tech and transportation is disappearing. đ One company is putting next-gen sensors and radar inside tomorrowâs EVs. đ The other is building the âneural networksâ on...
1 day ago â˘Â 8 min read
Issue #28 These drug manufacturers thrive on steady demand and innovation, not market moods. As inflation lingers and interest rates remain elevated, investors are shifting focus to sectors where demand doesnât flinch â even when the economy does. Healthcare, especially drug manufacturing, stands out as one of the few industries where pricing power and necessity go hand in hand. đ One company is a global powerhouse, dominating oncology with billion-dollar blockbusters. đ The other is...
3 days ago â˘Â 9 min read
Issue #28 High rates, big data, and a retail revolution these stocks are built for whatâs next The brokerage industry is undergoing a major transformationâwhere technology, interest rates, and investor behavior are redefining what âwinningâ looks like. Some firms are thriving on efficiency, automation, and institutional precision, while others are winning over retail traders with sleek design and accessibility. As we approach year-end, investors face a key question: which model will lead the...
4 days ago â˘Â 10 min read
Issue #28 One fighting the opioid crisis, the other mastering biosimilars each could deliver powerful returns in the next 12 months. The healthcare sector is entering a new growth cycleâdriven by innovation, cost efficiency, and a global push toward accessible treatment. From specialty drugs reshaping addiction therapy to generics powering affordability, two very different paths are defining the next era of pharma. As we move toward 2026, investors face a familiar question: is the smarter bet...
7 days ago â˘Â 10 min read
Issue #28 One global premium powerhouse. One deep-value turnaround play. Both could climb higher than you think. The outdoor gear market is shifting fastâfrom premium lifestyle brands that dominate global shelves to niche players fighting for a turnaround. Inflation, tariffs, and changing consumer habits have separated the winners from those just trying to stay on the trail. As we head into the final stretch of 2025, investors are asking one question: is it better to back proven profit...
8 days ago â˘Â 9 min read
Issue #28 Are You Missing Out? ZIP & UPWK Are Trading at a 20% Discount Hiring is in a strange place: budgets are tight, full-time roles are scarce, and yet the work keeps piling up. Thatâs creating two very different plays for investors. Upwork (NASDAQ: UPWK) is leaning into an AI-powered, on-demand talent model that lets companies scale work without headcount bloat. ZipRecruiter (NYSE: ZIP) is a high-beta bet on the U.S. hiring cycleâwhen the âGreat Freezeâ thaws, job postings and paid...
9 days ago â˘Â 12 min read
Issue #28 Oneâs drilling for growth - otherâs fueling Brazilâs energy revival As oil prices stabilize and global energy demand strengthens, two small-cap energy names under $5 are positioning themselves for outsized gains. One is a nimble U.S. shale producer leveraging partnerships to ramp up output. The other is a Brazilian downstream giant executing a disciplined growth plan backed by dividends and infrastructure investments. đ Looking for a debt-free U.S. oil play with explosive upside? đ...
10 days ago â˘Â 11 min read
Issue #28 The $5 Stock Duo We're Watching Right Now (Before Earnings Surge) đ As Q4 earnings season heats up, two small-cap stocks under $5 are quietly building momentumâand could be ready to surprise the market. On one side, Emerald Holding (NYSE: EEX) is staging a comeback in live B2B events, turning post-pandemic recovery into real revenue growth. On the other, Zedge (AMEX: ZDGE) is transforming from a ringtone relic into a profitable AI-driven content platform built for the creator...
11 days ago â˘Â 11 min read
Issue #28 One just launched an FDA-approved cancer drug. The other could cure Rett syndrome. As biotech momentum accelerates, two breakthrough companies are defining the sectorâs next phase of growth. On one side, Nuvation Bio (NYSE: NUVB) is evolving from a clinical-stage name into a commercial oncology powerhouse, riding the success of its newly approved cancer drug. On the other, Taysha Gene Therapies (NASDAQ: TSHA) is chasing a potential cure for Rett syndrome with full FDA alignment and...
14 days ago â˘Â 10 min read